Dyslipidemia

Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and those with hyperlipidemia vs. placebo and other lipid-lowering therapies, Merck reported.

PHILADELPHIA — Hypertension treatment and the role of cortisol in cardio-renal-metabolic health were among the featured topics from this year’s Heart in Diabetes CME Conference, according to Richard E. Pratley, MD.

PHILADELPHIA — Lipid management for woman requires personalized care that considers sex-specific conditions across the reproductive lifespan, particularly during pregnancy, Pam R. Taub, MD, said during the Heart in Diabetes CME Conference.

Obicetrapib plus ezetimibe combination therapy nearly halved LDL for patients with atherosclerotic heart disease or at high risk for it already taking maximally tolerated lipid-lowering therapy, researchers reported.

Among adults with thyroid cancer, those with hypoparathyroidism after a thyroidectomy may have increased risk for several complications such as diabetes, hypertension and dyslipidemia, researchers reported.

Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside increasing evidence for novel cholesterol-lowering medications, including PCSK9 inhibitors.

CHICAGO — A nurse-coordinated intensive intervention program emphasizing lifestyle and behavioral changes after ACS was associated with a 30% reduction in major adverse CV events for patients, primarily driven by a reduction in nonfatal MI.

Glomerular hyperfiltration may increase CVD risks, including myocardial infarction and heart failure, for patients with type 2 diabetes, study data show.

Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting newer medications that could be added to statin therapy or used on patients intolerant to statins.

Roche announced its next generation assay received FDA 510(k) clearance for the measurement of lipoprotein(a) for assessment of CV risk.